You are here

  • Home
  • Archive
  • Volume 9, Issue 11
  • Toripalimab plus intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma: an open-label single-arm, phase II trial

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Toripalimab plus intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma: an open-label single-arm, phase II trial

 

Online download statistics by month:

Online download statistics by month: November 2021 to March 2024

AbstractFullPdf
Nov 2021309308156
Dec 202114814873
Jan 2022919261
Feb 2022979764
Mar 202210010167
Apr 2022788146
May 202211411450
Jun 202210310550
Jul 2022899230
Aug 202210811061
Sep 202213213245
Oct 202210310344
Nov 2022595943
Dec 2022464526
Jan 2023384035
Feb 2023828240
Mar 2023495034
Apr 2023424235
May 2023505148
Jun 2023494936
Jul 2023505039
Aug 2023454529
Sep 2023666946
Oct 2023525239
Nov 2023626231
Dec 2023525242
Jan 2024515230
Feb 2024484837
Mar 2024585852
Total237123891389